Transplant diagnostics are tests that are performed pre and post-transplant procedures to check the compatibility between the donor and recipient of organ and its suitability in the body. It is mainly required to reduce the risk of organ rejection that can take place due to incompatible donors. Post-transplant, series of diagnostics tests are performed to check the chances of organ rejection.
The world transplant diagnostics market is projected to reach $1,031 million by 2022 and this growth is fueled by factors such as increasing elderly population, increased incidences of chronic disease patients, and increased focus on R&D. The market for transplant diagnostics is flanked with technological progression that is stimulated by increasing awareness related importance of organ donations. Although these factors will drive the market for transplant diagnostics there are certain elements that can limit the growth of the market. Worldwide scenario for organ shortage and difficulties in HLA sequencing can restrict the growth of the market.
The transplant diagnostics market is segmented on the basis of technology, components, application, end-users, type of organ, type of screening, and geography. The world transplant diagnostics market based on the technology is segmented into non-molecular assay and molecular assay technologies. The non-molecular assay technologies are further categorized as serological assay and Mixed Lymphocyte Culture (MLC) assay. The molecular assay technology is categorized into PCR-based and sequencing based. The global transplant diagnostics market based on the components is classified into instruments, reagents and consumables, and software and services. The transplant diagnostics market based on end-user is categorized as hospitals and transplant centers, research laboratories and academic institutes, and commercial service provider. On the bases of applications, the transplant diagnostics market is broadly classified into research and diagnostics. Further the market based on the type of organ is segmented into kidney, liver, heart, lung, pancreas, and others. On the bases of type of screening the market is categorized into pre-transplant screening and post-transplant screening.
BY GEOGRAPHY the market is divided into North America, Europe, Asia Pacific and ROW including further segmentation of the major countries. The key players in the transplant diagnostics market are focused on strategies such as product approval and launches, merger and acquisition, expansion, collaboration etc. to expand their market share.
KEY BENEFITS FOR STAKEHOLDERS:
This report provides an extensive analysis of the current and emerging market trends and dynamics in the world transplant diagnostics market.
In-depth analysis has been done in this report by constructing market estimations for the
Key market segments between 2014 and 2022.
Comprehensive analysis of factors that drive and restrict the growth of the world transplant diagnostics market is provided.
Exhaustive analysis of the world transplant diagnostics market
BY TECHNOLOGY helps in understanding the current range of the product available for commercial usage.
Competitive intelligence helps in understanding the competitive scenario across the geographies
Key market players within the world transplant diagnostics market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of the market.
Key market segments:
World transplant diagnostics market is segmented as:
Mixed Lymphocyte Culture
Instrument and Equipment
Reagent and consumables
Software and services
Hospitals and transplant centers
Research laboratories and academic institutes
Commercial Service Providers
By Organ Type
By Screening Type
Rest of North America
Rest of Europe
Rest of Asia-Pacific
Rest of LAMEA
1.1 Report description
1.2 Key Benefits
1.3 Key Market Segments
1.4 Research Methodology
1.4.1 Saecondary Research
1.4.2 Primary Research
1.4.3 Analyst Tools and Models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO Perspective
CHAPTER 3 MARKET OVERVIEW
3.1 Market Definition and Scope
3.2 Key Findings
3.2.1 Top Investment Pockets
3.2.2 Top Winning Strategies
3.3 Porters Five Forces Analysis
3.3.1 Bargaining Power of Suppliers
3.3.2 Bargaining Power of Buyers
3.3.3 Threat of New Entrants
3.3.4 High Intensity of Rivalry
3.3.5 Threat of Substitutes
3.4 Top Player Positioning, 2015
3.5 Market Dynamics
18.104.22.168 Increasing aging population
22.214.171.124 Increased incidence of chronic diseases
126.96.36.199 Increased focus on R&D
188.8.131.52 organ shortage worldwide
184.108.40.206 Difficulties in HLA sequencing
220.127.116.11 Shift from traditional methods to modern techniques for HLA typing
18.104.22.168 Increasing demand for organ transplant procedures
22.214.171.124 Mergers & acquisitions
CHAPTER 4 WORLD TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY
4.1.1 Market Size and Forecast
4.2 Non-Molecular Assays
4.2.1 Key Market Trends
4.2.2 Key Growth Factors and Opportunities
4.2.3 Market Size and Forecast
4.2.4 Serological Assays
126.96.36.199 Market size and forecast
4.2.5 Mixed Lymphocyte Culture Assays
188.8.131.52 Market size and forecast
4.3 Molecular Assays
4.3.1 Key Market Trends
4.3.2 Key Growth Factors and Opportunities
4.3.3 Market Size and Forecast
184.108.40.206 PCR-based molecular assay
220.127.116.11 Market size and forecast
18.104.22.168 sequencing-based molecular assay
22.214.171.124 Market size and forecast
CHAPTER 5 WORLD TRANSPLANT DIAGNOSTICS MARKET, BY COMPONENT
5.2 Consumables and Reagents
5.2.1 Market Size and Forecast
5.3 Instruments and Equipment
5.3.1 Market Size and Forecast
5.4 Software and Services
5.4.1 Market Size and Forecast
CHAPTER 6 WORLD TRANSPLANT DIAGNOSTICS MARKET, BY END USER
6.1.1 Market Size and Forecast
6.2 Hospitals and Transplant Centers
6.2.1 Market Size and Forecast
6.3 Research Laboratories and Academic Institutions
6.3.1 Market Size and Forecast
6.4 Commercial Service Providers
6.4.1 Market Size and Forecast
CHAPTER 7 WORLD TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION
7.2.1 Market Size and Forecast
7.3.1 Market Size and Forecast
CHAPTER 8 WORLD TRANSPLANT DIAGNOSTICS MARKET BY ORGAN TYPE
8.2.1 Market size and forecast
8.3.1 Market size and forecast
8.4.1 Market size and forecast
8.5.1 Market size and forecast
8.6.1 Market size and forecast
8.7.1 Market size and forecast
CHAPTER 9 WORLD TRANSPLANT DIAGNOSTICS MARKET, BY TYPE OF SCREENING
9.2 Pretransplant Screening
9.2.1 Market Size and Forecast
9.3 Posttransplant Screening
9.3.1 Market Size and Forecast
CHAPTER 10 WORLD TRANSPLANT DIAGNOSTICS MARKET, BY GEOGRAPHY
10.1.1 Market Size and Forecast
10.2 North America
10.2.1 Key Market Trends
10.2.2 Key Growth Factors and Opportunities
10.2.3 Market Size and Forecast
10.2.4 U.S.: Market Size and Forecast
10.2.5 Canada: Market Size and Forecast
10.2.6 Mexico: Market Size and Forecast
10.3.1 Key Market Trends
10.3.2 Key Growth Factors and Opportunities
10.3.3 Market Size and Forecast
10.3.4 UK: Market Size and Forecast
10.3.5 Germany: Market Size and Forecast
10.3.6 France: Market Size and Forecast
10.3.7 Spain: Market Size and Forecast
10.3.8 Italy: Market Size and Forecast
10.3.9 Turkey: Market Size and Forecast
10.3.10 Rest of Europe: Market Size and Forecast
10.4.1 Key Market Trends
10.4.2 Key Growth Factors and Opportunities
10.4.3 Market Size and Forecast
10.4.4 Australia: Market Size and Forecast
10.4.5 South Korea: Market Size and Forecast
10.4.6 New Zealand: Market Size and Forecast
10.4.7 China: Market Size and Forecast
10.4.8 Japan: Market Size and Forecast
10.4.9 Rest of Asia-Pacific: Market Size and Forecast
10.5.1 Key Market Trends
10.5.2 Key Growth Factors and Opportunities
10.5.3 Market Size and Forecast
10.5.4 Brazil: Market Size and Forecast
10.5.5 Israel: Market Size and Forecast
10.5.6 Iran: Market Size and Forecast
10.5.7 Saudi Arabia: Market Size and Forecast
10.5.8 Rest of LAMEA: Market Size and Forecast
CHAPTER 11 COMPANY PROFILES
11.1 Immucor, Inc. (TPG Capital)
11.1.1 Company overview
11.1.2 Operating business segments
11.1.3 Business performance
11.1.4 Key strategic moves & developments
11.2 Bio-Rad Laboratories, Inc.
11.2.1 Company overview
11.2.2 Operating business segments
11.2.3 Business performance
11.2.4 Key strategic moves & developments
11.3 Thermo Fisher Scientific Inc.
11.3.1 Company overview
11.3.2 Operating business segments
11.3.3 Business performance
11.3.4 Key strategic moves & developments
11.4 F. Hoffmann-la Roche AG
11.4.1 Company overview
11.4.2 Operating business segments
11.4.3 Business performance
11.4.4 Key strategic moves & developments
11.5 Illumina, Inc.
11.5.1 Company overview
11.5.2 Operating business segments
11.5.3 Business performance
11.5.4 Key strategic moves & developments
11.6 Abbott Laboratories
11.6.1 Company overview
11.6.2 Operating business segments
11.6.3 Business performance
11.6.4 Key strategic moves & developments
11.7 Sigma-Aldrich Corporation
11.7.1 Company overview
11.7.2 Operating business segments
11.7.3 Business performance
11.8 Qiagen N.V.
11.8.1 Company overview
11.8.2 Operating business segments
11.8.3 Business performance
11.8.4 Key strategic moves & developments
11.9 Olerup SSP AB (Allenex)
11.9.1 Company overview
11.9.2 Key strategic moves & developments
11.10 DiaSorin S.P.A.
11.10.1 Company overview
11.10.2 Operating business segments
11.10.3 Business performance
11.10.4 Key strategic moves & developments
Increase in incidence of organ failure owing to growing cases of chronic diseases, rise in ageing population, and increase in focus on R&D is expected to propel the growth of the global transplant diagnostics market. Chronic diseases can lead to organ failure in patients, which could be a significant target audience for transplant diagnostics procedures. However, difficulties in human leukocyte antigen (HLA) sequencing and increasing worldwide organ shortage can hamper the market growth.
The reagents & consumables segment accounted for the maximum revenue generation in 2015, owing to the increased number of diagnostics procedures pre and post organ transplantation. The instruments & equipment segment is projected to grow at a CAGR of 9.1% and reach $76.3 million by 2022. Both the technologies, namely non molecular assay and molecular assay hold significant position in the global transplant diagnostics market. However, molecular assay technology segment is projected to grow at the highest CAGR of 12.3%, due to highly accurate results provided by the modern molecular assay technology.
With rise in number of kidney transplants, the segment is set to report a high revenue in the future, with a CAGR of 9.8%, owing to increased incidence of renal failure worldwide. Liver and heart transplants are estimated to report a strong growth rate during the forecast duration, due to increased awareness for organ donations and increase in incidence of liver and heart failure.
Key Findings of the Transplant Diagnostics Market:
In the year 2015, reagents & consumables generated the highest revenue, and is projected to grow at a CAGR of 10%.
Software segment is projected to grow at the highest CAGR of 13.4%.
Kidney transplants is the major surgical procedure that requires transplant diagnostics.
The molecular assay segment is expected grow at a CAGR of 12.3%.
U.S. is the leading country and is projected to grow at a CAGR 9.9%.
In Asia-Pacific, South Korea led in 2015 and is expected to grow at a CAGR of 10.4%.
North America accounted for a major market share in 2015, with maximum revenue contribution from the U.S., due to large number of transplant procedures of kidney, liver, lung, heart, and pancreas. Adoption of latest technology and increase in awareness regardingorgan transplantation in the U.S. have boosted the North American transplant diagnostics market. The Asia-Pacific region offers lucrative opportunities for transplant diagnostics market players to expand their market presence. This region has the highest geriatric population, and the scenario is estimated to continue; further felling market growth for transplant diagnostics.
The major players have adopted product approval & launch as their key strategy to cater to the volatile industry needs and merger & acquisition to strengthen their brand value, product portfolio, and market position. Development of novel products incorporated with innovative technology supplemented with aggressive acquisition activity are the instrumental strategies adopted by leading players. The key players profiled in this report include Immucor, Inc. (TGI Capital), Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc. F. Hoffmann-la Roche AG, Illumina Inc., Abbott Laboratories, Sigma-Aldrich Corporation, Qiagen N. V., Olerup SSP AB (Allenex), and Diasorin S.P.A. Thermo Fisher occupies a major share in the transplant diagnostics market, owing to its novel product portfolio and diverse geographical presence.